NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Trametinib

Last Revision: December 3, 2018.

Estimated reading time: 1 minute

CASRN: 871700-17-3

Chemical structure

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of trametinib during breastfeeding. Because trametinib is 97% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 3.9 to 4.8 days and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during trametinib therapy and for 4 months after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Trametinib

CAS Registry Number

871700-17-3

Drug Class

  • Breast Feeding
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Protein Kinase Inhibitors
  • Signal Transduction Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate).[ACS Med Chem Lett. 2011]
    Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate).
    Abe H, Kikuchi S, Hayakawa K, Iida T, Nagahashi N, Maeda K, Sakamoto J, Matsumoto N, Miura T, Matsumura K, et al. ACS Med Chem Lett. 2011 Apr 14; 2(4):320-4. Epub 2011 Feb 28.
  • Review Cobimetinib[Drugs and Lactation Database (...]
    Review Cobimetinib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Gilteritinib[Drugs and Lactation Database (...]
    Review Gilteritinib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Sonidegib[Drugs and Lactation Database (...]
    Review Sonidegib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Palbociclib[Drugs and Lactation Database (...]
    Review Palbociclib
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...